Status:
TERMINATED
Use of PET-CT in the Management of Crohn's Disease
Lead Sponsor:
Columbia University
Conditions:
Crohn's Disease
Eligibility:
All Genders
21-65 years
Brief Summary
Crohn's disease (CD) is an autoimmune disorder which affects over 700,000 people in the U.S. The disease can vary in severity and multiple drug classes are available to the disease depending on diseas...
Detailed Description
Crohn's disease (CD) is a gastrointestinal autoimmune disease thought to result from exposure to luminal antigen. This exposure then results in a robust Th1 mediated immune response which is not downr...
Eligibility Criteria
Inclusion
- Diagnosis of Crohn's disease
- CDAI1\>220
- Identification of small bowel disease based on an imaging study (CT scan, Abdominal ultrasound, MRI), colonoscopy, or histopathology 4. Need for initiation of biologic therapy to control disease process.
Exclusion
- Abdominal surgery within 8 wks of study entry
- Change in dose of steroids or immunomodulators within 2wks of study entry
- Pregnancy
- Active bacterial infection or undrained abscess
- Any contraindications to initiation of AntiTNF therapy (i.e. latent tuberculosis).
Key Trial Info
Start Date :
February 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2013
Estimated Enrollment :
5 Patients enrolled
Trial Details
Trial ID
NCT01182467
Start Date
February 1 2011
End Date
September 1 2013
Last Update
April 10 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Columbia University Medical Center
New York, New York, United States, 10032